

Hai Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4228289/publications.pdf>

Version: 2024-02-01

123
papers

2,243
citations

218677

26
h-index

315739

38
g-index

126
all docs

126
docs citations

126
times ranked

2605
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond. <i>European Journal of Medicinal Chemistry</i> , 2022, 231, 114142.	5.5	31
2	Recent advances in poly(ionic liquid)s for biomedical application. <i>Biomaterials Science</i> , 2022, 10, 2524-2539.	5.4	12
3	Ionic Liquids for Enhanced Drug Delivery: Recent Progress and Prevailing Challenges. <i>Molecular Pharmaceutics</i> , 2022, 19, 1033-1046.	4.6	21
4	Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2022, , .	6.4	1
5	Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis. <i>European Journal of Medicinal Chemistry</i> , 2022, 234, 114253.	5.5	4
6	Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. <i>European Journal of Medicinal Chemistry</i> , 2022, 233, 114191.	5.5	9
7	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel. <i>European Journal of Medicinal Chemistry</i> , 2022, 233, 114231.	5.5	7
8	Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. <i>Bioorganic Chemistry</i> , 2021, 106, 104492.	4.1	11
9	Protein corona-guided tumor targeting therapy via the surface modulation of low molecular weight PEG. <i>Nanoscale</i> , 2021, 13, 5883-5891.	5.6	15
10	Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N-(5,6-diphenyl-5,6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors. <i>Chemical Biology and Drug Design</i> , 2021, 97, 1117-1128.	5.8	3
11	Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6179-6197.	6.4	18
12	Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia. <i>Bioorganic Chemistry</i> , 2021, 111, 104849.	4.1	10
13	Design, synthesis and immunological evaluation of self-assembled antigenic peptides from dual-antigen targets: a broad-spectrum candidate for an effective antibreast cancer therapy. , 2021, 9, e002523.		7
14	Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists. <i>Bioorganic Chemistry</i> , 2021, 115, 105229.	4.1	7
15	Exploration of novel anti-angiogenic PEDF-derived peptides with improved activities by inhibiting proliferation, suppressing migration, and inducing 67LR internalization. <i>Bioorganic Chemistry</i> , 2021, 116, 105323.	4.1	2
16	Source and exploration of the peptides used to construct peptide-drug conjugates. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113712.	5.5	13
17	A designed cyclic peptide based on Trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability. <i>Bioorganic Chemistry</i> , 2021, 117, 105453.	4.1	9
18	Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties. <i>Bioorganic Chemistry</i> , 2020, 95, 103538.	4.1	9

#	ARTICLE	IF	CITATIONS
19	Development of cell-permeable peptide-based PROTACs targeting estrogen receptor $\hat{\pm}$. <i>European Journal of Medicinal Chemistry</i> , 2020, 187, 111967.	5.5	29
20	Novel HLA-A2 restricted antigenic peptide derivatives with high affinity for the treatment of breast cancer expressing NY-ESO-1. <i>Bioorganic Chemistry</i> , 2020, 103, 104138.	4.1	4
21	GLP-1R agonists for the treatment of obesity: a patent review (2015-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 781-794.	5.0	14
22	Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115601.	3.0	10
23	Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115574.	3.0	12
24	Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide. <i>European Journal of Medicinal Chemistry</i> , 2020, 194, 112236.	5.5	7
25	Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells. <i>European Journal of Medicinal Chemistry</i> , 2020, 189, 112051.	5.5	9
26	A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice. <i>Pharmacological Research</i> , 2020, 153, 104679.	7.1	16
27	Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5458-5476.	6.4	27
28	Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 608-622.	5.5	16
29	Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115070.	3.0	2
30	Discovery to solve multidrug resistance: Design, synthesis, and biological evaluation of novel agents. <i>Archiv Der Pharmazie</i> , 2019, 352, e1900127.	4.1	9
31	Design, synthesis and biological evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide derivatives as novel P-glycoprotein inhibitors reversing multidrug resistance. <i>Bioorganic Chemistry</i> , 2019, 86, 166-175.	4.1	12
32	Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 433-445.	5.5	13
33	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3347-3357.	3.0	22
34	Design, synthesis and biological evaluation of novel 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as potential BRD4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2813-2821.	3.0	15
35	Synthesis and evaluation of redox-sensitive gonadotropin-releasing hormone receptor-targeting peptide conjugates. <i>Bioorganic Chemistry</i> , 2019, 88, 102945.	4.1	4
36	Synthesis and anti-cancer evaluation of folic acid-peptide-paclitaxel conjugates for addressing drug resistance. <i>European Journal of Medicinal Chemistry</i> , 2019, 171, 104-115.	5.5	15

#	ARTICLE	IF	CITATIONS
37	Histology and antitumor activity study of PTX-loaded micelle, a fluorescent drug delivery system prepared by PEG-TPP. <i>Chinese Chemical Letters</i> , 2019, 30, 1083-1088.	9.0	47
38	Design, synthesis and biological evaluation of N1-(isoquinolin-5-yl)-N2-phenylpyrrolidine-1,2-dicarboxamide derivatives as potent TRPV1 antagonists. <i>Bioorganic Chemistry</i> , 2019, 82, 100-108.	4.1	4
39	Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2599-2609.	3.0	12
40	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2420-2427.	3.0	14
41	Injectable self-assembled peptide hydrogels for glucose-mediated insulin delivery. <i>Biomaterials Science</i> , 2018, 6, 1480-1491.	5.4	37
42	Preparation and Pharmaceutical Characterizations of Lipidated Dimeric <i>Xenopus</i> Glucagon-Like Peptide-1 Conjugates. <i>Bioconjugate Chemistry</i> , 2018, 29, 390-402.	3.6	16
43	Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 703-711.	3.0	10
44	Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2632-2639.	3.0	12
45	Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. <i>Medicinal Research Reviews</i> , 2018, 38, 381-425.	10.5	67
46	Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists. <i>Bioorganic Chemistry</i> , 2018, 76, 303-313.	4.1	12
47	Screening of novel RGD peptides to modify nanoparticles for targeted cancer therapy. <i>Biomaterials Science</i> , 2018, 6, 125-135.	5.4	33
48	pH-Sensitive micelles with mitochondria-targeted and aggregation-induced emission characterization: synthesis, cytotoxicity and biological applications. <i>Biomaterials Science</i> , 2018, 6, 2998-3008.	5.4	16
49	Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 814-831.	5.5	29
50	Design, synthesis and evaluation of a novel series of inhibitors reversing P-glycoprotein-mediated multidrug resistance. <i>Chemical Biology and Drug Design</i> , 2018, 92, 1708-1716.	3.2	15
51	Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. <i>Chemical Biology and Drug Design</i> , 2018, 92, 1547-1554.	3.2	2
52	Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold. <i>Bioorganic Chemistry</i> , 2018, 80, 296-302.	4.1	10
53	Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 4567-4573.	3.0	13
54	pH-sensitive peptide hydrogel for glucose-responsive insulin delivery. <i>Acta Biomaterialia</i> , 2017, 51, 294-303.	8.3	118

#	ARTICLE	IF	CITATIONS
55	Design, synthesis and biological evaluation of peptide dendrimers with wound healing promoting activity. <i>Medicinal Chemistry Research</i> , 2017, 26, 580-586.	2.4	21
56	A novel mitochondria-targeting fluorescent probe for hydrogen sulfide in living cells. <i>Chemical Biology and Drug Design</i> , 2017, 90, 167-174.	3.2	9
57	Performance of Doxorubicin-Conjugated Gold Nanoparticles: Regulation of Drug Location. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 8569-8580.	8.0	64
58	Synthesis, spectroscopic characterization, crystal structure, and biological evaluation of a diorganotin(IV) complex with 2-acetylpyridine <i>N</i> -cyclohexylthiosemicarbazone. <i>Inorganic and Nano-Metal Chemistry</i> , 2017, 47, 813-817.	1.6	6
59	Design, synthesis and structure-activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2445-2450.	3.0	19
60	Design, synthesis and biological evaluation of novel peptides as potential agents with anti-tumor and multidrug resistance-reversing activities. <i>Amino Acids</i> , 2017, 49, 1355-1364.	2.7	5
61	Synthesis and biological evaluation of novel peptides based on antimicrobial peptides as potential agents with antitumor and multidrug resistance-reversing activities. <i>Chemical Biology and Drug Design</i> , 2017, 90, 972-980.	3.2	16
62	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4194-4202.	3.0	9
63	Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. <i>Bioorganic Chemistry</i> , 2017, 72, 116-122.	4.1	29
64	Design, Synthesis, and Pharmacological Characterization of Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3289-3302.	6.4	34
65	Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2930-2943.	6.4	36
66	Reversal of P-glycoprotein-mediated multidrug resistance and pharmacokinetics study in rats by WYX-5. <i>Canadian Journal of Physiology and Pharmacology</i> , 2017, 95, 580-585.	1.4	3
67	Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. <i>Amino Acids</i> , 2017, 49, 1831-1841.	2.7	6
68	A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 1158-1169.	5.5	33
69	Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 458-479.	5.5	31
70	Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane. <i>Amino Acids</i> , 2017, 49, 1601-1610.	2.7	28
71	Synthesis of Analogues of BCTC Incorporating a Pyrrolidinyl Linker and Biological Evaluation as Transient Receptor Potential Vanilloid 1 Antagonists. <i>Chemical Biology and Drug Design</i> , 2016, 87, 306-311.	3.2	9
72	Design, Synthesis, and Biological Evaluation of Novel Cholesteryl Peptides with Anticancer and Multidrug Resistance-Reversing Activities. <i>Chemical Biology and Drug Design</i> , 2016, 87, 374-381.	3.2	9

#	ARTICLE	IF	CITATIONS
73	Phenylbutazone, a New Long-Acting Agent that can Improve the Peptide Pharmacokinetic Based on Serum Albumin as a Drug Carrier. <i>Chemical Biology and Drug Design</i> , 2016, 87, 936-945.	3.2	8
74	Design, synthesis and biological evaluation of 4-aminopyrimidine-5-carbaldehyde oximes as dual inhibitors of c-Met and VEGFR-2. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3353-3358.	3.0	24
75	Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists. <i>RSC Advances</i> , 2016, 6, 46356-46365.	3.6	22
76	Design, synthesis and biological evaluation of LBM-A5 derivatives as potent P-glycoprotein-mediated multidrug resistance inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2287-2297.	3.0	28
77	Design, synthesis and biological evaluation of novel triazole-core reversal agents against P-glycoprotein-mediated multidrug resistance. <i>RSC Advances</i> , 2016, 6, 25819-25828.	3.6	13
78	Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 871-890.	4.1	78
79	Site-specific fatty chain-modified exenatide analogs with balanced gluco regulatory activity and prolonged in vivo activity. <i>Biochemical Pharmacology</i> , 2016, 110-111, 80-91.	4.4	19
80	Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5449-5454.	3.0	20
81	Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1981-1987.	3.0	34
82	Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 849-857.	3.0	10
83	Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. <i>European Journal of Medicinal Chemistry</i> , 2016, 113, 246-257.	5.5	51
84	Design, Synthesis and <i>In Vivo</i> Evaluation of Novel <i>N</i> -Aryl Glucosides as Potent Sodium-Dependent Glucose Cotransporters Inhibitors for the Treatment of Diabetes. <i>Chemical Biology and Drug Design</i> , 2015, 86, 764-775.	3.2	3
85	Design, Synthesis, and Biological Evaluation of Novel Peptide Gly ³ -MC ₆₂ Analogues as Potential Antidiabetic Agents. <i>Chemical Biology and Drug Design</i> , 2015, 86, 979-989.	3.2	2
86	Novel Pentapeptide $\text{GLP-1} (32-36)$ Amide Inhibits I^2 -Cell Apoptosis <i>In Vitro</i> and Improves Glucose Disposal in Streptozotocin-Induced Diabetic Mice. <i>Chemical Biology and Drug Design</i> , 2015, 86, 1482-1490.	3.2	12
87	Aliphatic acid-conjugated antimicrobial peptides – potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 7673-7680.	2.8	9
88	Design, synthesis and biological evaluation of novel peptide MC2 analogues from <i>Momordica charantia</i> as potential anti-diabetic agents. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 4551-4561.	2.8	25
89	Synthesis and in vitro anti-cancer evaluation of luteinizing hormone-releasing hormone-conjugated peptide. <i>Amino Acids</i> , 2015, 47, 2359-2366.	2.7	7
90	Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6666-6672.	3.0	31

#	ARTICLE	IF	CITATIONS
91	Coumaglutide, a novel long-acting GLP-1 analog, inhibits β -cell apoptosis in vitro and invokes sustained glycemic control in vivo. <i>European Journal of Pharmacology</i> , 2015, 767, 211-219.	3.5	15
92	The quantitative detection of the uptake and intracellular fate of albumin nanoparticles. <i>RSC Advances</i> , 2015, 5, 34956-34966.	3.6	6
93	Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7158-7164.	3.0	21
94	6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as Superior Reversal Agents for P-Glycoprotein-Mediated Multidrug Resistance. <i>ChemMedChem</i> , 2015, 10, 336-344.	3.2	15
95	Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 132-140.	3.0	29
96	A High-Sensitivity Coumarin-Based Fluorescent Probe for Monitoring Hydrogen Sulfide in Living Cells. <i>Chemical Biology and Drug Design</i> , 2015, 86, 173-179.	3.2	7
97	Aryl Glucosides with Substituents at the Distal Aryl Ring as Sodium-Dependent Glucose Cotransporter Inhibitors for the Treatment of Diabetes Mellitus. <i>Chemical Biology and Drug Design</i> , 2015, 86, 246-253.	3.2	8
98	Evaluation of Anti-inflammatory and Analgesic Effects of Synthesized Derivatives of Ibuprofen. <i>Chemical Biology and Drug Design</i> , 2015, 85, 623-632.	3.2	10
99	Reversal of P-glycoprotein-mediated multidrug resistance by LBM-A5 in vitro and a study of its pharmacokinetics in vivo. <i>Canadian Journal of Physiology and Pharmacology</i> , 2015, 93, 33-38.	1.4	5
100	Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities. <i>European Journal of Medicinal Chemistry</i> , 2015, 89, 540-548.	5.5	31
101	Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. <i>British Journal of Pharmacology</i> , 2014, 171, 5252-5264.	5.4	41
102	Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 73, 105-111.	5.5	9
103	Discovery of Novel P-Glycoprotein-Mediated Multidrug Resistance Inhibitors Bearing Triazole Core via Click Chemistry. <i>Chemical Biology and Drug Design</i> , 2014, 84, 182-191.	3.2	20
104	Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6857-6866.	3.0	16
105	Design, Synthesis, and Biological Evaluation of Andrographolide Derivatives as Potent Hepatoprotective Agents. <i>Chemical Biology and Drug Design</i> , 2014, 83, 324-333.	3.2	27
106	Virtual Screening for Cholesterol Absorption Inhibitors. <i>Medicinal Chemistry</i> , 2014, 11, 2-12.	1.5	3
107	Design, Synthesis, and Biological Activity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9955-9968.	6.4	65
108	Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity. <i>Biochemical Pharmacology</i> , 2013, 86, 297-308.	4.4	40

#	ARTICLE	IF	CITATIONS
109	Evaluation of Hypoglycemic and Antioxidative Effects of Synthesized Peptide <sc>MC</sc>62. <i>Chemical Biology and Drug Design</i> , 2013, 82, 99-105.	3.2	12
110	Synthesis and Biological Evaluation of a Series of 6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-2-substituted Tetrahydroisoquinoline Derivatives. <i>Medicinal Chemistry</i> , 2012, 8, 711-716.	1.5	1
111	Synthesis and Biological Evaluation of Andrographolide Derivatives as Potent Anti-HIV Agents. <i>Archiv Der Pharmazie</i> , 2012, 345, 647-656.	4.1	20
112	A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. <i>Journal of Molecular Modeling</i> , 2012, 18, 2795-2804.	1.8	9
113	Structure-activity relationships of a snake cathelicidin-related peptide, BF-15. <i>Peptides</i> , 2011, 32, 2497-2503.	2.4	54
114	Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5934-5938.	2.2	20
115	Synthesis and biological evaluation of andrographolide derivatives as potent anti-HIV agents. <i>Chinese Chemical Letters</i> , 2011, 22, 781-784.	9.0	14
116	The first pharmacophore model for potent G protein-coupled receptor 119 agonist. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2901-2907.	5.5	23
117	Synthesis and Bioactivity Evaluation of Dipeptidyl Peptidase IV Resistant Glucagon-like Peptide-1 Analogues. <i>Protein and Peptide Letters</i> , 2010, 17, 1290-1295.	0.9	5
118	Solid phase synthesis of fatty acid modified glucagon-like peptide-1 (7-36) amide under thermal and controlled microwave irradiation. <i>Chinese Chemical Letters</i> , 2010, 21, 27-30.	9.0	8
119	Total synthesis of endothelin 1 by microwave-assisted solid phase method. <i>Chinese Chemical Letters</i> , 2010, 21, 388-390.	9.0	6
120	Synthesis and Biological Evaluation of Capsaicin Derivatives as Analgesia Drugs. <i>Letters in Drug Design and Discovery</i> , 2010, 7, 122-127.	0.7	2
121	Synthesis and Preliminary Biological Evaluation of Capsaicin Derivatives as Potential Analgesic Drugs. <i>Medicinal Chemistry</i> , 2010, 6, 205-210.	1.5	5
122	Synthesis and Preliminary Anti-HIV Activities of Andrographolide Derivatives. <i>Medicinal Chemistry</i> , 2010, 6, 252-258.	1.5	16
123	Microwave-assisted solid phase synthesis, PEGylation, and biological activity studies of glucagon-like peptide-1(7-36) amide. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7607-7614.	3.0	24